PubRank

Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Clinical Trial ID NCT00187005

PubWeight™ 19.01‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00187005

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002 11.83
2 Treatment of acute lymphoblastic leukemia. N Engl J Med 2006 11.30
3 Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet 2005 1.94
4 Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 2003 1.79
5 Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003 1.75
6 Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002 1.74
7 Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2004 1.65
8 Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005 1.53
9 Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR Am J Neuroradiol 2005 1.48
10 Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 2004 1.48
11 Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer 2007 1.47
12 Proxy assessment of quality of life in pediatric clinical trials: application of the Health Utilities Index 3. Qual Life Res 2005 1.44
13 Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood 2006 1.41
14 A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 2006 1.40
15 Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol 2001 1.38
16 Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002 1.28
17 Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood 2006 1.22
18 Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001 1.21
19 Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis. Pediatr Blood Cancer 2005 1.14
20 Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood 2006 1.10
21 Improving the segmentation of therapy-induced leukoencephalopathy in children with acute lymphoblastic leukemia using a priori information and a gradient magnitude threshold. Magn Reson Med 2004 1.10
22 Quality of life as conveyed by pediatric patients with cancer. Qual Life Res 2004 1.07
23 Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer 2004 1.03
24 A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2002 1.02
25 A quantitative MR imaging assessment of leukoencephalopathy in children treated for acute lymphoblastic leukemia without irradiation. AJNR Am J Neuroradiol 2005 1.02
26 Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 2004 1.00
27 A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics 2004 0.96
28 Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 2005 0.93
29 Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6-RUNX1 fusion, T-lineage immunophenotype, and favorable outcome. Cancer Genet Cytogenet 2006 0.89
30 Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. Clin Cancer Res 2002 0.86
31 Promoter polymorphisms in the β-2 adrenergic receptor are associated with drug-induced gene expression changes and response in acute lymphoblastic leukemia. Clin Pharmacol Ther 2010 0.76
Next 100